Progress in neuro-psychopharmacology & biological psychiatry
December 20, 2024
Guilherme Lodetti, Rafael Mariano de Bitencourt, Eduardo Pacheco Rico
9 citations
Alcohol is a harmful drug, and dependence on it is often resistant to treatment, with no completely effective model available. Classic psychedelics like LSD, psilocybin, and ayahuasca have shown promising pharmacotherapeutic effects in treating treatment-resistant conditions, including addiction, particularly alcohol dependence. This narrative review examines emerging research on psychedelics for alcohol use disorder treatment. These substances may treat addiction by modulating neuroplasticity in the brain. Since serotonergic psychedelics do not produce physical dependence or withdrawal symptoms with repeated use, they are considered promising treatment options. However, great inter-individual variability exists in the duration of effects, and further studies using different doses and protocols are needed.
Journal of Psychiatric Research
June 23, 2026
Júlio César Claudino Dos Santos, Sofia Januário Bolan, Guilherme Lodetti da Silva et al.
Psychedelic compounds such as psilocybin, LSD, MDMA, and ketamine are being explored as potential treatments for autism spectrum disorder (ASD), a condition marked by social communication deficits, repetitive behaviors, and sensory differences, often with anxiety and emotional dysregulation. These drugs may modulate serotonin and glutamate signaling, enhance neuroplasticity, and reorganize brain networks. Current evidence does not support treating core ASD symptoms like social communication deficits or repetitive behaviors, but psychedelics may help with associated issues such as social anxiety, emotional dysregulation, cognitive rigidity, and co-occurring mood symptoms. Direct clinical studies in ASD remain scarce, and ethical and safety concerns, especially for pediatric and neurodivergent populations, are noted.
Psychopharmacology
April 14, 2026
Guilherme Lodetti, Antonio Inserra, Henrique Redivo et al.
A single exposure to ayahuasca reversed behavioral and biochemical changes caused by 14 days of unpredictable chronic stress in adult zebrafish. Stressed fish showed impaired sociability, anxiety-like behavior, hyperactivity, elevated whole-body cortisol, and reduced whole-brain BDNF. Ayahuasca restored sociability, reduced anxiety-like behavior and hyperactivity, normalized cortisol levels, and increased BDNF. These findings suggest ayahuasca can reverse stress-induced behavioral and neuroendocrine alterations, supporting further clinical studies for chronic stress.
Neuroscience
January 22, 2026
Guilherme Lodetti, Gislaine Zilli Réus, Eduardo Pacheco Rico
Fewer than half of patients with major depressive disorder achieve remission with standard pharmacotherapy, and many cannot tolerate it. This narrative review examines classic psychedelics as an alternative treatment. These substances primarily bind to 5-HT2A receptors, increasing connectivity between sensory and motor brain networks. They generate long-term behavioral responses comparable to traditional antidepressants. Clinical and experimental studies show that classic psychedelics alleviate depressive symptoms. The mood improvement is thought to stem from effects on neuroplasticity, including neurogenesis and related signaling pathways.